Article

New Vulnerability in Aggressive Leukemia Discovered by Researchers

04/09/2026

Excerpt from the Press Release: A potential weakness in a common form of leukemia could lead to new treatments. The discovery, made by researchers at the Lewis Katz School of Medicine at Temple University, shows that leukemia cells with mutations in DNMT3A—a gene often altered in acute myeloid leukemia (AML)—depend on a DNA-repair enzyme known as DNA polymerase…

Abcuro Presents Results from Phase 2/3 MUSCLE Study of Ulviprubart in Patients with Inclusion Body Myositis at GCOM 2026

04/08/2026

Excerpt from the Press Release: NEWTON, Mass.–(BUSINESS WIRE)–Abcuro, Inc., a clinical stage biotechnology company, today presented results at the 6th Global Conference on Myositis (GCOM) meeting, being held March 23-26, 2026 in Lisbon, Portugal from the Phase 2/3 MUSCLE clinical study of ulviprubart (ABC008), an investigational monoclonal antibody in development for the treatment of patients…

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

04/06/2026

Pralsetinib induced robust and durable responses with a manageable safety profile, reinforcing the benefits of selective RET inhibitors in treating RET fusion-positive NSCLC Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 31, 2026 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced publication…

RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

04/01/2026

TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027 Select TIGeR-PaC Cancer Centers Now Using RenovoCath® as a Stand-Alone Device for Drug-Delivery in Oncology Management Excerpt from the Press Release: MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or “the Company”)…

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

03/31/2026

78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes Excerpt from the Press Release: SAN DIEGO, March 26, 2026 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its…

GentiBio Announces First Participant Dosed in POLARIS Phase 1 Clinical Trial of GNTI-122 in Recently Diagnosed Type 1 Diabetes

03/27/2026

Milestone marks first clinical evaluation of a targeted cell therapy designed to preserve natural insulin production POLARIS trial enrolling at 10 specialized clinic sites across the U.S. GentiBio on track to present key data in latter part of 2026 and 1H 2027  Excerpt from the Press Release: CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ — GentiBio, Inc.,…

Pilatus Biosciences Announces First Patient Dosed in Phase 1 Trial of First-in-Class Metabolic Checkpoint Antibody PLT012 in Solid Tumors

03/26/2026

First-in-human study underway evaluating anti-CD36 monoclonal antibody designed to restore metabolic fitness in exhausted T cells, reduce immunosuppressive cells, and enhance antitumor immunity Excerpt from the Press Release: DOVER, Del. & EPALINGES, Switzerland–(BUSINESS WIRE)–Pilatus Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced the first patient…

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

03/25/2026

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 Pivotal Noninferiority Trial Expected in the Fourth Quarter of 2026 At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity and…

Freenome Reports Data for Multiomic Blood-Based Screening Test for Lung Cancer

03/24/2026

The data, generated from a study designed to optimize ongoing test refinement, will be presented at the AACR Annual Meeting in April Excerpt from the Press Release: BRISBANE, Calif., March 18, 2026 /PRNewswire/ — Freenome, an early cancer detection company developing blood-based screening tests, today announced initial development data for its investigational lung cancer screening…

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

03/18/2026

– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of –1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong efficacy data in new analyses, including reduction in nasal congestion score (NCS) by -0.96 (p < 0.0001) – Excerpt from the Press Release:…